[1]赖子梅,王 珊.β受体阻滞剂治疗婴幼儿血管瘤的研究进展[J].医学信息,2019,32(09):54-57.[doi:10.3969/j.issn.1006-1959.2019.09.018]
　LAI Zi-mei,WANG Shan.Progress in the Study of β-blockers in the Treatment of Infantile Hemangiomas[J].Journal of Medical Information,2019,32(09):54-57.[doi:10.3969/j.issn.1006-1959.2019.09.018]
点击复制

β受体阻滞剂治疗婴幼儿血管瘤的研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年09期
页码:
54-57
栏目:
综述
出版日期:
2019-05-01

文章信息/Info

Title:
Progress in the Study of β-blockers in the Treatment of Infantile Hemangiomas
文章编号:
1006-1959（2019）09-0054-04
作者:
赖子梅; 王 珊
（重庆医科大学附属儿童医院肿瘤外科/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国家国际科技合作基地/儿科学重庆市重点实验室，重庆 400014）
Author(s):
LAI Zi-mei; WANG Shan
(Department of Oncology,Children's Hospital Affiliated to Chongqing Medical University/Key Laboratory of Child Developmental Disease Research,Ministry of Education/National International Science and Technology Cooperation Base for Children's Developmental
关键词:
婴幼儿血管瘤; β受体阻滞剂; 普萘洛尔
Keywords:
Infantile hemangiomas; β-blockers; Propranolol
分类号:
R732.2
DOI:
10.3969/j.issn.1006-1959.2019.09.018
文献标志码:
A
摘要:
婴幼儿血管瘤（IH）是婴幼儿期最常见的良性肿瘤，大部分病变可自然消退，多以随访观察为主，但对可引起严重并发症或功能障碍的中、高风险IH仍主张尽早干预及治疗。普萘洛尔为非选择性β受体阻滞剂，自2008年开始应用于IH治疗后经大量临床实验及系列研究疗效得到验证，目前已成为IH治疗的一线药物。随着人们对IH认识的进一步深入及普萘洛尔相关治疗机制的探索，近年来其他β受体阻滞剂类药物治疗IH的报道逐渐增多，其在IH的应用范围逐渐扩大，药物选择相应增多。本文简要综述目前β受体阻滞剂应用于IH治疗的相关进展，进一步探究其疗效及安全性，为IH临床治疗提供更多选择及参考依据。
Abstract:
Infantile hemangioma (IH) is the most common benign tumor in infants and young children. Most of the lesions can be resolved naturally. Most of them are followed up, but the medium and high risk IH can cause serious complications or dysfunction. Advocate early intervention and treatment. Propranolol is a non-selective beta blocker. It has been proven in clinical trials and series of studies since IH was applied in 2008. It has become the first-line drug for IH treatment. With the further understanding of IH and the exploration of propranolol-related therapeutic mechanisms, reports of other β-blockers in the treatment of IH have increased in recent years, and their application in IH has gradually expanded. increase. This article briefly reviews the current progress of β-blockers in the treatment of IH, further explores its efficacy and safety, and provides more options and reference for clinical treatment of IH.

参考文献/References:

[1]Soliman YS,Khachemoune A.Infantile hemangiomas:our current understanding and treatment options[J].Dermatol Online J,2018,24(9).
[2]Strumila A,Dagilyte RV,Virgilijus Beisa,et al.Recommendations and a guideline for referral of infantile haemangioma to tertiary centres[J].Acta Med Litu,2018,25(1):38-44.
[3]Puttgen KB.Diagnosis and management of infantile hemangiomas[J].Pediatr Clin North Am,2014,61(2):383-402.
[4]Drolet BA,Frommelt PC,Chamlin SL,et al.Initiation and use of propranolol for infantile hemangioma:report of a consensus conference[J].Pediatrics 2013,131(1):128-140.
[5]Babiak-Choroszczak L,Gizewska-Kacprzak K,Dawid G,et al.Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas[J].Adv Clin Exp Medicine,2019.
[6]Munden A,Butschek R,Tom WL,et al.Prospective study of infantile haemangiomas:incidence, clinical characteristics and association with placental anomalies[J].Br J Dermatol,2014,170(4): 907-913.
[7]Goelz R,Poets CF.Incidence and treatment of infantile haemangioma in preterm infants[J].Arch Dis Child Fetal Neonatal Ed,2015,100(1):F85-F91.
[8]Castren E,Salminen P,Vikkula M,et al.Inheritance patterns of infantile hemangioma[J].Pediatrics,2016,138(5):e20161623.
[9]Darrow DH,Greene AK,Mancini AJ,et al.Diagnosis and management of infantile hemangioma[J].Pediatrics,2015,136(4):e1060-e1104.
[10]Dompmartin A.Classification of vascular anomalies[J].Ann Dermatol Venereol,2013,140(5):337-339.
[11]Rotter A,de Oliveira ZNP.Infantile hemangioma: pathogenesis and mechanisms of action of propranolol[J].J Dtsch Dermatol Ges,2017,15(12):1185-1190.
[12]Ji Y,Chen S,Xu C,et al.The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action[J].Br J Dermatol,2015,172(1):24-32.
[13]Hagen R,Ghareeb E,Jalali O.Infantile hemangiomas:what have we learned from propranolol?[J].Current Opinion in Pediatrics,2018,30(4):499-504.
[14]Lin Z,Wang L,Huang G,et al.Propranolol inhibits the activity of PI3K,AKT,and HIF-1α in infantile hemangiomas[J].Pediatric Surgery International,2018,34(11):1233-1238.
[15]Sun B,Dong C,Lei H,et al.Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway[J].Chem Biol Interact,2018(294):28-33.
[16]Zhao F,Yang X,Xu G,et al.Propranolol suppresses HUVEC viability, migration,VEGF expression, and promotes apoptosis by downregulation of miR-4295[J].J Cell Biochem,2019,120(4): 6614-6623.
[17]Wei L,Li L,Zhang B.Propranolol Suppresses Cobalt Chloride-Induced Hypoxic Proliferation in Human Umbilical Vein Endothelial Cells in vitro[J].Pharmacology,2018,103(1-2):61-67.
[18]Del Frari L,Léauté-Labrèze C,Guibaud L,et al.Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations[J].Pharmacology Research & Perspectives,2018,6(3):e00399.
[19]Drolet BA,Frommelt PC,Chamlin SL,et al.Initiation and use of propranolol for infantile hemangioma:report of a consensus conference[J].Pediatrics,2013,131(1):128-140.
[20]Zhou W,He S,Yang Y,et al.Formulation,characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma[J].Drug DevelOpment and Industrial Pharmacy,2015,41(7):1109-1119.
[21]Léauté-Labrèze C,Hoeger P,Mazereeuw-Hautier J,et al.A randomized, controlled trial of oral propranolol in infantile hemangioma[J].The New England Journal of Medicine,2015,372(8):735-746.
[22]Saqi L,Zvulunov A,Lapidoth M,et al.Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases[J].Dermatology,2014,228(2):136-144.
[23]Chang L,Ye X,Qiu Y,et al.Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China[J].Annals of plastic surgery,2016,76(5):559-563.
[24]Hoeger PH,Harper JI,Baselga E,et al.Treatment of infantile haemangiomas:recommendations of a Accepted Article This article is protected by copyright[J].Eur J Pediatr,2015,174(4):855-865.
[25]Bayart CB,Tamburro JE,Vidimos AT,et al.Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase:A Retrospective Noninferiority Study[J].Pediatric Dermatology,2017,34(4):413-421.
[26]Wang Q,Xiang B,Chen S,et al.Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review[J].Australas J Dermatol,2018.
[27]Abarzúa-Araya A,Navarrete-Dechent CP,Heusser F,et al.Atenolol versus propranolol for the treatment of infantile hemangiomas:A randomized controlled study[J].J Am Acad Dermatol,2014,70(6):1045-1049.
[28]de Graaf M,Raphael MF,Breugem CC,et al.Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group[J]. J Plast Reconstr Aesthet Surg,2013,66(12):1732-1740.
[29]Randhawa HK,Sibbald C,Garcia Romero MT.Oral Nadolol for the Treatment of Infantile Hemangiomas: A Single-Institution Retrospective Cohort Study[J].Pediatric Dermatology, 2015,32(5):690-695.
[30]Bernabeu-Wittel J,Narváez-Moreno B,de la Torre-García JM,et al.Oral Nadolol for Children with Infantile Hemangiomas and Sleep Disturbances with Oral Propranolol[J].Pediatric dermatology,2015,32(6):853-857.
[31]Pope E,Chakkittakandiyil A,Lara-Corrales I,et al.Expanding the therapeutic repertoire of infantile haemangiomas: Cohort-blinded study of oral nadolol compared with propranolol[J].Br J Dermatol,2013,168(1):222-224.
[32]Chan H,McKay C,Adams S,et al.RCT of timolol maleate gel for superficial Infantile hemangiomas in 5- to 24-weekolds[J].Pediatrics,2013,131(6)：e1739-e1747.
[33]Chakkittakandiyil A,Phillips R,Frieden IJ,et al.Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: A retrospective, multicenter, cohort study[J].Pediatr Dermatol,2012,29(1):28-31.
[34]Chambers CB,Katowitz WR,Katowitz JA,et al.A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas[J].Ophthal Plast Reconstr Surg,2012,28(2):103-106.
[35]Wu HW,Wang X,Zhang L,et al.Topical Timolol Vs Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas[J].Frontiers in Oncology,2018(8):605.

相似文献/References:

[1]李 铎.β受体阻滞剂预处理对AMI介入治疗患者心室重构、 自主神经功能恢复的影响研究[J].医学信息,2018,31(09):91.[doi:10.3969/j.issn.1006-1959.2018.09.027]
　LI Duo.Effect of β-blocker Preconditioning on Ventricular Remodeling and Autonomic Nerve Function Recovery in Patients Undergoing AMI Intervention[J].Journal of Medical Information,2018,31(09):91.[doi:10.3969/j.issn.1006-1959.2018.09.027]
[2]邵俊丽.静息心率与脑卒中关系的研究[J].医学信息,2018,31(16):16.[doi:10.3969/j.issn.1006-1959.2018.16.006]
　SHAO Jun-li.Research on Relationship between Resting Heart Rate and Stroke[J].Journal of Medical Information,2018,31(09):16.[doi:10.3969/j.issn.1006-1959.2018.16.006]

更新日期/Last Update: 2019-05-01